PMC:7195088 / 7366-7637 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"200","span":{"begin":213,"end":231},"obj":"Chemical"}],"attributes":[{"id":"A200","pred":"tao:has_database_id","subj":"200","obj":"MESH:D006886"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"stigational studies. When this is unfeasible, off-label use may be considered according to local protocols and consent procedures. In view of the absence of evidence, we are currently unable to support the use of hydroxychloroquine in asymptomatic or mildly symptomatic n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":50,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"stigational studies. When this is unfeasible, off-label use may be considered according to local protocols and consent procedures. In view of the absence of evidence, we are currently unable to support the use of hydroxychloroquine in asymptomatic or mildly symptomatic n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T31","span":{"begin":50,"end":55},"obj":"Chemical"},{"id":"T32","span":{"begin":213,"end":231},"obj":"Chemical"}],"attributes":[{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"stigational studies. When this is unfeasible, off-label use may be considered according to local protocols and consent procedures. In view of the absence of evidence, we are currently unable to support the use of hydroxychloroquine in asymptomatic or mildly symptomatic n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T52","span":{"begin":21,"end":130},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"stigational studies. When this is unfeasible, off-label use may be considered according to local protocols and consent procedures. In view of the absence of evidence, we are currently unable to support the use of hydroxychloroquine in asymptomatic or mildly symptomatic n"}